相关实验视频
Updated: Jan 14, 2026

07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
在差异化甲状腺癌中,潜在的分子治疗点的高患病率
Vanessa Zambelli1, Giulia Orlando2, Marta Fornaro1
1Department of Oncology, University of Turin, at San Luigi Hospital, Regione Gonzole 10, Orbassano, Turin, 10043, Italy.
Endocrine pathology
|October 22, 2025
概括
差异化甲状腺癌 (PDTC) 有不同的分子子组. 识别可向突变和MMR缺陷为这种罕见的癌症提供了新的个性化治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 差差分化的甲状腺癌 (PDTC) 是一种罕见的,激进的甲状腺癌.
- 对于不可切除的PDTC,有效的治疗选择有限.
- 分子特征对于确定治疗点至关重要.
研究的目的:
- 为了进行PDTC的分子特征.
- 在PDTC亚型中识别潜在的治疗点.
- 为了研究基因突变,融合和不匹配修复 (MMR) 蛋白质状态.
主要方法:
- 下一代测序 (NGS) 用于DNA和RNA分析.
- 对于MMR蛋白表达的免疫组织化学.
- 在样本子集中的基因融合的分析.
主要成果:
- NRAS和TP53突变是最常见的,相互排斥的变异 (分别为25%).
- 在19.6%的病例中发生了TERT促进子突变.
- 在9%的病例中发现了可向的基因融合,包括一种新的TBL1XR1::PIK3CA融合.
结论:
- 在基因组上,PDTC可以分为不同的子组.
- 47%的PDTC病例存在可向突变或MMR缺陷,这表明个性化治疗的潜力.
- 发现了像TBL1XR1::PIK3CA这样的新型基因融合,为PDTC治疗开辟了新的途径.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Synthesis and Regulation of Thyroid Hormones
7.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.2K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

